Diana Smith
About Diana Smith
Diana Smith is the Associate Director of Global Compliance at Bristol-Myers Squibb in Summit, New Jersey, with over 16 years of experience in global compliance.
Current Role at Bristol-Myers Squibb
Diana Smith currently holds the position of Associate Director Global Compliance at Bristol-Myers Squibb, located in Summit, New Jersey. In this role, she leverages her extensive experience in compliance to oversee global compliance initiatives. She focuses on ensuring adherence to regulatory standards and best practices within the company.
Previous Experience at Celgene
Diana Smith worked at Celgene in 2007, where she served in two distinct roles: Associate Director Product Quality Surveillance and Associate Director Global GMP/GDP Compliance. Although her tenure in these roles was brief, her work was centered on maintaining product quality and compliance with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards.
Regulatory Compliance Expertise at PLIVA
From 2005 to 2007, Diana Smith held the position of Sr. Manager Regulatory Compliance at PLIVA. During her two years in this role, she was responsible for ensuring that the company's regulatory practices met the required standards. Her work in regulatory compliance included collaborating with various departments to align regulatory strategies with operational goals.
Investigations Role at Alpharma
Between 2003 and 2005, Diana Smith served as Sr. Manager Investigations at Alpharma. In this capacity, she conducted detailed investigations to uphold regulatory compliance and address any regulatory issues. Her role involved working closely with both internal and external stakeholders to ensure compliance and mitigate risks.
Educational Background in Pharmaceutical and Chemical Studies
Diana Smith pursued her higher education at Fairleigh Dickinson University, where she studied Pharmaceutical and Chemical Studies. She also achieved a Master of Business Administration (MBA) from the same institution, completing her studies between 1989 and 1994. Her educational background provides a strong foundation in both the scientific and business aspects of the pharmaceutical industry.